z-logo
open-access-imgOpen Access
The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors
Author(s) -
Karin Haustermans
Publication year - 2013
Publication title -
american society of clinical oncology educational book
Language(s) - English
Resource type - Journals
eISSN - 1548-8756
pISSN - 1548-8748
DOI - 10.1200/edbook_am.2013.33.e151
Subject(s) - gastroesophageal junction , medicine , randomized controlled trial , radiation therapy , esophagogastric junction , disease , incidence (geometry) , adenocarcinoma , chemotherapy , clinical trial , meta analysis , esophageal adenocarcinoma , surgery , oncology , cancer , physics , optics
Adenocarcinoma of the gastroesophageal junction (GE-junction) is a frequent disease with a rising incidence. The optimal treatment of localized disease is the subject of many randomized trials and meta-analyses studying the role of preoperative chemotherapy or preoperative chemoradiation compared with surgery alone. A complicating factor in interpreting the results of these trials is the fact that GE-junction tumors are sometimes regarded as esophageal tumors, although in other studies they are regarded as gastric cancers. A thorough review of the literature including meta-analyses clearly indicates that there is a role for preoperative chemoradiation in locally advanced GE-junction tumors. Based on the available evidence a surgery alone arm in future randomized trials for locally advanced GE junction tumors can no longer be regarded as a standard arm.status: publishe

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom